Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 2/2012

01-06-2012 | Review Article

Nanoparticles targeting HLA-G for gene therapy in cancer

Authors: Ines Zidi, Nidhal Ben Amor

Published in: Medical Oncology | Issue 2/2012

Login to get access

Abstract

Cancer cells are aided by immune-tolerant functions of HLA-G to escape the immune surveillance. In general, cancer cells can express membranous HLA-G, secrete soluble HLA-G, produce HLA-G positive exosomes, and can be subjected to proteolytic cleavage by matrix metalloproteinases releasing shedding HLA-G1 in stressful conditions. Thus, the downregulation of HLA-G either in transcripts or proteins may affect positively cancer therapy. The aim of this study was to examine the molecular nanoparticles targeting HLA-G. Special focus was accorded to RNA interference particles. Although numerous studies have reported the importance of HLA-G gene expression modulation by nanoparticles, no studies have investigated clinically their efficiency in this modulation.
Literature
1.
Rouas-Freiss N, et al. The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? Proc Natl Acad Sci USA. 1997;94:5249–54.PubMedCrossRef
2.
Le Gal F, et al. HLA-G mediated-inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol. 1999;11:101–6.
3.
Riteau B, et al. HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis. J Immunol. 2001;166:5018–26.PubMed
4.
Marchal-Bras-Goncalves R, et al. A soluble HLA-G protein that inhibits natural killer cell-mediated cytotoxicity. Transplant Proc. 2001;33:2355–9.PubMedCrossRef
5.
Le Rond S, et al. Alloreactive CD4+ and CD8+ T cells express the immunotolerant HLA-G molecule in mixed lymphocyte reactions : in vivo implications in transplanted patients. Eur J Immunol. 2004;34:649–60.PubMedCrossRef
6.
Lila N, et al. Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism. Proc Natl Acad Sci USA. 2001;98:12150–5.PubMedCrossRef
7.
Amiot L, Ferrone S, Grosse-Wilde H, Seliger B. Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention? Cell Mol Life Sci. 2011;68(3):417–31.PubMedCrossRef
8.
Kanai T, et al. Human leukocyte antigen-G-expressing cells differently modulate the release of cytokines from mononuclear cells present in the decidua versus peripheral blood. Am J Reprod Immunol. 2001;45(2):94–9.PubMedCrossRef
9.
Kanai T, et al. Soluble HLA-G influences the release of cytokines from allogeneic peripheral blood mononuclear cells in culture. Mol Hum Reprod. 2001;7(2):195–200.PubMedCrossRef
10.
Le Rond S, et al. Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/regulatory T cells. J Immunol. 2006;176(5):3266–76.PubMed
11.
Chen HX, et al. Upregulation of human leukocyte antigen-G expression and its clinical significance in ductal breast cancer. Hum Immunol. 2010;71(9):892–8.PubMedCrossRef
12.
Gregori S, et al. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood. 2010;116(6):935–44.PubMedCrossRef
13.
Park GM, et al. Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis. Biochem Biophs Res Commun. 2004;313:606–11.CrossRef
14.
Le Maoult J, Zafaranloo K, Le Danff C, Carosella ED. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J. 2005;19:662–4.
15.
Moreau P, Flajollet S, Carosella ED. Non-classical transcriptional regulation of HLA-G: an update. J Cell Mol Med. 2009;13(98):2973–89.PubMedCrossRef
16.
Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res. 2005;65:10139–44.PubMedCrossRef
17.
Rouas-Freiss N, et al. Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. Semin Cancer Biol. 2007;17(6):413–21.PubMedCrossRef
18.
Riteau B, et al. Exosomes bearing HLA-G are released by melanoma cells. Hum Immunol. 2003;64(11):1064–72.PubMedCrossRef
19.
Sebti Y, et al. Expression of functional soluble human leucocyte antigen-G molecules in lymphoproliferative disorders. Br J Haematol. 2007;138(2):202–12.PubMedCrossRef
20.
Dong DD, et al. Human leukocyte antigen-G (HLA-G) expression in cervical lesions: association with cancer progression, HPV 16/18 infection, and host immune response. Reprod Sci. 2010;17(8):718–23.PubMedCrossRef
21.
Basta P, et al. The Immunohistochemical analysis of RCAS1, HLA-G, and B7H4-positive macrophages in partial and complete hydatidiform mole in both applied therapeutic surgery and surgery followed by chemotherapy. Am J Reprod Immunol. 2011;65(2):164–72.PubMedCrossRef
22.
Singer G, et al. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res. 2003;9(12):4460–4.PubMed
23.
Kleinberg L, et al. Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch. 2006;449(1):31–9.PubMedCrossRef
24.
Jain KK. The handbook of nanomedicine. Totowa: Humana Press; 2008.
25.
Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature. 2001;409(6818):363–6.PubMedCrossRef
26.
Snustad DP, Simmons MJ. Principles of genetics. 4th ed. Hoboken: Wiley; 2006.
27.
Nicholl DST. An introduction to genetic engineering. 3rd ed. New York: Cambridge University Press; 2008.
28.
Tokatlian T, Segura T. siRNA applications in nanomedecine. Nanomed Nanobiotechnol. 2010;2:305–15.CrossRef
29.
Ford LP, Toloue MM. Delivery of RNAi mediators. RNA. 2010;1:341–50.PubMed
30.
Wengenmayer T, Poehlmann TG, Markert UR. Inhibition of HLA-G production in JEG-3 choriocarcinoma cells by RNA interference. Am J Reprod Immunol. 2004;51(3):189–91.PubMedCrossRef
31.
Chen JH, et al. Construction of eukaryotic expression plasmid expressing siRNA targeting HLA-G gene and detection of its specific downregulation effect. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2007;23(5):409–12.PubMed
32.
Chen CL, Liao QP. Role of human leukocyte antigen-G small interference RNA in a choriocarcinoma cell line. Zhonghua Fu Chan Ke Za Zhi. 2005;40(8):549–52.PubMed
33.
Drenzek JG, et al. Suppression of mamu-AG by RNA interference. Am J Reprod Immunol. 2009;61(6):453–61.PubMedCrossRef
34.
Figueiredo C, Horn PA, Blasczyk R, Seltsam A. Regulating MHC expression for cellular therapeutics. Transfusion. 2007;47:18–27.PubMedCrossRef
35.
Chen LJ, et al. Inhibition of HLA-G expression via RNAi abolishes resistance of extravillous trophoblast cell line TEV-1 to NK lysis. Placenta. 2010;31(6):519–27.PubMedCrossRef
36.
37.
38.
Rossbach M. Therapeutic implications of microRNAs in human cancer. J Nucleic Acids Investig. 2011;2:e2.
39.
Sethupathy P, Collins FS. MicroRNA target site polymorphisms and human disease. Trends Genet. 2008;24(10):489–97.PubMedCrossRef
40.
Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev. 2009;28:369–78.PubMedCrossRef
41.
Bandiera S, Hatem E, Lyonnet S, Henrion-Caude A. microRNAs in diseases: from candidate to modifier genes. Clin Genet. 2010;77:306–13.PubMedCrossRef
42.
George GP, Mittal RD. MicroRNAs: potential biomarkers in cancer. Indian J Clin Biochem. 2010;25(1):4–14.CrossRef
43.
O’Day E, Lal A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res. 2010;12(2):201.PubMedCrossRef
44.
Yang L, Belaguli N, Berger DH. MicroRNA and colorectal cancer. World J Surg Oncol. 2009;33(4):638–46.
45.
Veit TD, Chies JA. Tolerance versus immune response–microRNAs as important elements in the regulation of the HLA-G gene expression. Transpl Immunol. 2009;20(4):229–31.PubMedCrossRef
46.
Tan Z, et al. Allele-specific targeting of microRNAs to HLA-G and risk of asthma. Am J Hum Genet. 2007;81(4):829–34.PubMedCrossRef
47.
Zhu XM, et al. Overexpression of miR-152 leads to reduced expression of human leukocyte antigen-G and increased natural killer cell mediated cytolysis in JEG-3 cells. Am J Obstet Gynecol. 2010;202(6):592.e1–7.CrossRef
48.
Castelli EC, et al. In silico analysis of microRNAS targeting the HLA-G 3′ untranslated region alleles and haplotypes. Hum Immunol. 2009;70(12):1020–5.PubMedCrossRef
49.
John M, et al. Gene silencing by RNAi in mammalian cells. Current Protocols in Molecular Biology. New York: Wiley; 2003. p. 26.2.1–2.14.
50.
Iorns E, Lord CJ, Turner N, Ashworth A. Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov. 2007;6:556–68.PubMedCrossRef
51.
52.
Chang CC, Murphy SP, Ferrone S. Differential in vivo and in vitro HLA-G expression in melanoma cells: potential mechanisms. Hum Immunol. 2003;64(11):1057–63.PubMedCrossRef
53.
Moreau P, et al. HLA-G gene repression is reversed by demethylation. Proc Natl Acad Sci USA. 2003;100(3):1191–6.PubMedCrossRef
54.
Mouillot G, et al. HLA-G gene activation in tumor cells involves cis-acting epigenetic changes. Int J Cancer. 2005;113(6):928–36.PubMedCrossRef
55.
Yan WH, Lin AF, Chang CC, Ferrone S. Induction of HLA-G expression in a melanoma cell line OCM-1A following the treatment with 5-aza-2′-deoxycytidine. Cell Res. 2005;15(7):523–31.PubMedCrossRef
56.
Polakova K, et al. Modulation of HLA-G expression. Neoplasma. 2007;54(6):455–62.PubMed
57.
Dunker K, et al. Expression and regulation of non-classical HLA-G in renal cell carcinoma. Tissue Antigens. 2008;72(2):137–48.PubMedCrossRef
58.
Menendez L, et al. Epigenetic changes within the promoter region of the HLA-G gene in ovarian tumors. Mol Cancer. 2008;7:43.PubMedCrossRef
59.
Poláková K, Bandzuchová E, Kuba D, Russ G. Demethylating agent 5-aza-2′-deoxycytidine activates HLA-G expression in human leukemia cell lines. Leuk Res. 2009;33(4):518–24.PubMedCrossRef
60.
Polakova K, et al. Activation of HLA-G expression by 5-aza-2-deoxycytidine in malignant hematopoetic cells isolated from leukemia patients. Neoplasma. 2009;56(6):514–20.PubMedCrossRef
61.
Qiu X, et al. Equitoxic doses of 5-azacytidine and 5-aza-2′deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptome. PLoS One. 2010;5(9):e12994.PubMedCrossRef
62.
Vrba L, et al. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS One. 2010;5(1):e8697.PubMedCrossRef
63.
64.
Metadata
Title
Nanoparticles targeting HLA-G for gene therapy in cancer
Authors
Ines Zidi
Nidhal Ben Amor
Publication date
01-06-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-9942-8

Other articles of this Issue 2/2012

Medical Oncology 2/2012 Go to the issue

Original Paper

IGHV gene rearrangements as outcome predictors for CLL patients: experience of Ukrainian group

Original Paper

A retrospective statistical analysis of high-grade soft tissue sarcomas

Original Paper

Surgical outcomes of gastrointestinal stromal tumors of the stomach: a single unit experience in the era of targeted drug therapy

Original Paper

Down-regulation of lysyl oxidase-like 2 (LOXL2) is associated with disease progression in lung adenocarcinomas

Original Paper

PTP1B expression contributes to gastric cancer progression

Original Paper

Prostate-specific antigen: its relationship with alcohol intake and tobacco
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits